

# Technical Product Report

*For Research Use Only; Not for use in Diagnostic Procedures*

Product Description: Seraseq® 22q11 Male Twins – Matched cfDNA

Material Number: 0720-1116 Batch Number: 10737484

Material Description: A purified ccfDNA-like mixture of human genomic DNA (matched maternal and fetal) derived from an antepartum (or prenatal) pregnant patient's blood sample with a twin gestation identified as having a 22q11 microdeletion (DiGeorge Syndrome).

Date of Manufacture: 12 MAR 2025 Expiration Date: 28 OCT 2028

Diluent: 1 mM Tris, 0.1 mM EDTA, 10 mM KCl

Fill Volume: 25 µL

Storage: -20 °C

Concentration (Invitrogen™ Qubit™ dsDNA BR Assay): Nominal value: 10 ng/µL  
Average measured value for this batch: 13.9 ng/µL

Method used for NIPT: \*NIPTIFY Focus Plus test. This cell-free DNA test uses Focus Plus (Fragmented DNA Compact Sequencing Assay for enriched fetal material) technology. The Focus Plus technology analyzes fetal aneuploidies using whole-genome low-coverage Illumina sequencing and applies z-score-based risk assessment.

\*NIPTIFY test is validated exclusively for singleton pregnancies.

Fetal Fraction: 27.05%  
\*The fetal fraction has been enriched by the NIPTIFY® Focus Plus assay workflow. The average enrichment factor is 3.6, but efficiency may vary. For a male fetus, the NIPTIFY® Focus Plus fetal fraction estimation is based on FFY (fetal fraction based on Y-chromosome) and for a female fetus, it is based on the PREFACE (PREdict FetAI Component) algorithm. This fetal fraction is provided for information only and may depend on assays and methodologies used.

22q11 Result: High Risk for 22q11DS

Call for Fetal Gender: Male

**Approval:**



20 MAR 2025

Prepared By

Date